Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Mokenge Peter Malafa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2716-4315; OpenAlex author ID A5006838528; NIH RePORTER profile ID 1953942. Sources: ClinicalTrials.gov.

Their work

Papers
85 (first author 10, last author 22)
Trials
3 (principal investigator on 3)
Grants
2
Labs led
1
Collaborators
216
Papers, trials and grants by year

2011: 6 papers · 2012: 2 papers, 1 grant · 2013: 3 papers · 2014: 2 papers · 2015: 16 papers · 2016: 9 papers · 2017: 7 papers · 2018: 2 papers · 2019: 2 papers · 2020: 7 papers · 2021: 7 papers · 2022: 5 papers · 2023: 4 papers, 1 trial · 2024: 5 papers, 2 trials, 1 grant · 2025: 5 papers · 2026: 3 papers

Papers 50 of 85

  1. Targeting Oncomucin-Driven Immunosuppression Improves the Efficacy of K-ras G12D Inhibition in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.04.041↗
  2. Implementing Timely Germline Genetic Testing for Patients With Pancreatic Cancer Using a Genetics Copilot for Point-of-Care Education and Health Assessment. Co-author DOI 10.1200/po-25-00807↗
  3. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. First author DOI 10.6004/jnccn.2026.0046↗
  4. Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1038/s41698-025-01046-w↗
  5. Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s43856-025-01277-9↗
  6. The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-25-0237↗
  7. To irradiate or electroporate: how should we ablate pancreatic cancer? Co-author DOI 10.21037/tgh-24-164↗
  8. Association of Pathologic Response and Adjuvant Chemotherapy with Survival in Resected Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy. Co-author DOI 10.3390/cancers17111797↗
  9. Elevated Urinary Levels of Fungal and Environmental Toxins in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12029-024-01125-4↗
  10. Correction: Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.28556↗
  11. Stereotactic body radiotherapy plus rucosopasem in locally advanced or borderline resectable pancreatic cancer: GRECO-2 phase II study design. Co-author DOI 10.2217/fon-2022-1219↗
  12. Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of t… Co-author DOI 10.3389/fonc.2024.1362244↗
  13. The Evolving Role of Neoadjuvant Radiation Therapy in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/jcm13226800↗
  14. The impact of age and comorbidity on localized pancreatic cancer outcomes: A US retrospective cohort analysis with implications for surgical centralization. Co-author DOI 10.1016/j.sopen.2023.02.001↗
  15. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-control… Co-author DOI 10.1016/s1470-2045(23)00478-3↗
  16. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic R… Co-author DOI 10.1177/10732748221150228↗
  17. Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.28508↗
  18. Surgical approach to pancreaticoduodenectomy for pancreatic adenocarcinoma: uncomplicated ends justify the means. Co-author DOI 10.1007/s00464-021-08845-9↗
  19. Patient-caregiver dyads in pancreatic cancer: identification of patient and caregiver factors associated with caregiver well-being. Co-author DOI 10.1007/s10865-022-00354-x↗
  20. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection. Co-author DOI 10.1007/s11605-021-05130-x↗
  21. Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation … Co-author DOI 10.1016/j.adro.2022.101045↗
  22. Hospital Surgical Volume Is Poorly Correlated With Delivery of Multimodal Treatment for Localized Pancreatic Cancer: A National Retrospective Cohort Study. Co-author DOI 10.1097/as9.0000000000000197↗
  23. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis. Co-author DOI 10.1038/s41388-020-01564-w↗
  24. The Impact of Socioeconomic Deprivation on Clinical Outcomes for Pancreatic Adenocarcinoma at a High-volume Cancer Center: A Retrospective Cohort Analysis. Co-author DOI 10.1097/sla.0000000000003706↗
  25. Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-4781↗
  26. Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1200/po.20.00265↗
  27. The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pan… Co-author DOI 10.3390/cancers13040809↗
  28. Minimally invasive image-guided therapy of primary and metastatic pancreatic cancer. Co-author DOI 10.3748/wjg.v27.i27.4322↗
  29. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. First author DOI 10.6004/jnccn.2021.0017↗
  30. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis. Co-author DOI 10.1002/jso.26103↗
  31. Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s). Co-author DOI 10.1016/j.bbcan.2019.188318↗
  32. Completion of adjuvant therapy in patients with resected pancreatic cancer. Co-author DOI 10.1016/j.hpb.2019.07.008↗
  33. Targeting the IκB Kinase Enhancer and Its Feedback Circuit in Pancreatic Cancer. Last author DOI 10.1016/j.tranon.2019.11.009↗
  34. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice. Co-author DOI 10.1053/j.gastro.2019.11.279↗
  35. Case Report of Isolated Gastric Metastasis of Pancreatic Cancer From a Diagnostic Biopsy: Management of a Rare Oncologic Entity. Last author DOI 10.1177/1073274820904042↗
  36. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pa… Last author DOI 10.1186/s12885-020-07182-9↗
  37. Vitamin E δ-tocotrienol sensitizes human pancreatic cancer cells to TRAIL-induced apoptosis through proteasome-mediated down-regulation of c-FLIPs. Last author DOI 10.1186/s12935-019-0876-0↗
  38. Pancreatic Adenocarcinoma, Version 1.2019. First author DOI 10.6004/jnccn.2019.0014↗
  39. Endoscopic Ultrasound-Based Pancreatic Cancer Screening of High-Risk Individuals: A Prospective Observational Trial. First author DOI 10.1097/mpa.0000000000001038↗
  40. Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy. Co-author DOI 10.21037/jgo.2017.09.13↗
  41. Case report: Irreversible electroporation for locally advanced pancreatic cancer. Last author DOI 10.1016/j.ijscr.2017.08.052↗
  42. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy… Co-author DOI 10.1080/0284186x.2016.1256497↗
  43. Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/pai.0000000000000368↗
  44. TGFβ1 overexpression is associated with improved survival and low tumor cell proliferation in patients with early-stage pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.13533↗
  45. δ-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis. Last author DOI 10.18632/oncotarget.15767↗
  46. Outcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy. Co-author DOI 10.21037/jgo.2017.08.05↗
  47. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. First author DOI 10.6004/jnccn.2017.0131↗
  48. Outcome Disparities in Pancreatic Cancer: Need for Improved Regionalization of Care. First author DOI 10.1001/jamasurg.2015.4221↗
  49. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal… Last author DOI 10.1016/j.surg.2016.04.039↗
  50. Increased Expression of the Glucose Transporter Type 1 Gene Is Associated With Worse Overall Survival in Resected Pancreatic Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000000580↗

Trials 3

  1. Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer Principal investigator NCT06378047↗
  2. Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3) Principal investigator NCT06519097↗
  3. Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations Principal investigator NCT05687188↗

Grants 2

  1. Novel Therapy to Inhibit IPMN Progression R01CA263575↗
  2. Intervention of Pancreatic Oncogenic Pathways with Dietary Tocotrienol R01CA129227↗

Closest collaborators

The 25 strongest of 216 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pamela Joy Hodul · 34 shared papers, 2011–2026 · strength 3.52
  2. Jason B. Fleming · 18 shared papers, 2020–2025 · strength 2.59
  3. Sarah E. Hoffe · 24 shared papers, 2011–2026 · strength 2.43
  4. Jennifer B. Permuth · 10 shared papers, 1 shared trial, 2015–2026 · strength 2.00
  5. Jason W. Denbo · 12 shared papers, 2020–2025 · strength 1.94
  6. José M. Pimiento · 19 shared papers, 2013–2025 · strength 1.92
  7. Surinder K. Batra · 6 shared papers, 1 shared grant, 2019–2026 · strength 1.79
  8. Jessica M. Frakes · 15 shared papers, 2015–2025 · strength 1.76
  9. Barbara Ann Centeno · 13 shared papers, 2011–2026 · strength 0.99
  10. Dae Won Kim · 6 shared papers, 2021–2025 · strength 0.99
  11. Dae Won Kim · 6 shared papers, 2021–2026 · strength 0.93
  12. Kazim M. Husain · 13 shared papers, 2011–2021 · strength 0.83
  13. John Michael Bryant · 4 shared papers, 2022–2025 · strength 0.81
  14. Benjamin Daniel Powers · 6 shared papers, 2020–2023 · strength 0.74
  15. Gregory M. Springett · 15 shared papers, 2011–2017 · strength 0.72
  16. Domenico Coppola · 11 shared papers, 2011–2020 · strength 0.69
  17. Daniel A. Anaya · 5 shared papers, 2016–2023 · strength 0.68
  18. Dung‐Tsa Chen · 9 shared papers, 2012–2025 · strength 0.67
  19. Ravi Shridhar · 13 shared papers, 2011–2017 · strength 0.65
  20. Jose Gilberto Trevino · 5 shared papers, 2016–2025 · strength 0.58
  21. Richard D. Kim · 5 shared papers, 2015–2026 · strength 0.58
  22. Brian G. Czito · 7 shared papers, 2012–2026 · strength 0.55
  23. Robert A. Wolff · 7 shared papers, 2012–2026 · strength 0.55
  24. Margaret A. Park · 3 shared papers, 2025–2026 · strength 0.55
  25. Saı̈d M. Sebti · 8 shared papers, 2011–2021 · strength 0.51

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.